Lista de obras - David T Teachey - Dominio Público Uruguay

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

scientific article published on 18 February 2019

Atypical Chronic Myeloid Leukemia in Two Pediatric Patients.

artículo científico publicado en 2015

Autoimmune lymphoproliferative syndrome: more than a FAScinating disease.

artículo científico publicado en 2017

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

artículo científico publicado en 2015

CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition

scientific article published on 18 July 2019

Cellular therapy: Immune-related complications

artículo científico publicado en 2019

Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia

scientific article published on 25 September 2020

Chimeric antigen receptor T cells for sustained remissions in leukemia

artículo científico publicado en 2014

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

artículo científico publicado en 2013

Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia

artículo científico publicado en 2019

Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome

scientific article published on 04 September 2020

Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.

artículo científico publicado en 2016

Cytokine Release Syndrome after Haploidentical Stem Cell Transplantation.

artículo científico publicado en 2016

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

artículo científico publicado en 2013

Deep Immune Profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19

artículo científico publicado en 2020

Development of hemolytic paroxysmal nocturnal hemoglobinuria without graft loss following hematopoietic stem cell transplantation for acquired aplastic anemia

scientific article published on 22 March 2019

Diagnosis and management of autoimmune cytopenias in childhood

artículo científico publicado en 2013

Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases.

artículo científico publicado en 2017

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.

artículo científico publicado en 2015

Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.

artículo científico publicado en 2015

Excellent outcomes for patients with B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses

artículo científico publicado en 2019

Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors

artículo científico publicado en 2018

Hypofibrinogenemia Is Associated With Poor Outcome and Secondary Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome in Pediatric Severe Sepsis.

artículo científico publicado en 2018

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

artículo científico publicado en 2016

Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia

artículo científico publicado en 2022

JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.

artículo científico publicado en 2017

Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model.

artículo científico publicado en 2014

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

artículo científico publicado en 2014

Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy

artículo científico publicado en 2016

Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function.

artículo científico publicado en 2017

Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia

artículo científico publicado en 2021

Neurotoxicity after CTL019 in a pediatric and young adult cohort

artículo científico publicado en 2018

New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome

artículo científico publicado en 2012

Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling.

artículo científico publicado en 2011

Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children

artículo científico publicado en 2016

PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia

article

Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction

artículo científico publicado en 2021

Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia.

artículo científico publicado en 2016

Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice.

artículo científico publicado en 2011

Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)

artículo científico publicado en 2006

Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop

artículo científico publicado en 2010

Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?

artículo científico publicado en 2015

Severe Mucha-Habermann-Like Ulceronecrotic Skin Disease in T-Cell Acute Lymphoblastic Leukemia Responsive to Basiliximab and Stem Cell Transplant

artículo científico publicado en 2017

Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial

artículo científico publicado en 2015

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

artículo científico publicado en 2020

Somatic ALPS: a FAScinating condition

artículo científico publicado en 2010

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date

artículo científico publicado en 2020

Statins are active in acute lymphoblastic leukaemia (ALL): a therapy that may treat ALL and prevent avascular necrosis.

artículo científico publicado en 2011

Successful Treatment of Recurrent Autoimmune Cytopenias in the Context of Sinus Histiocytosis With Massive Lymphadenopathy Using Sirolimus.

artículo científico publicado en 2015

T-cell acute lymphoblastic leukemia.

artículo científico publicado en 2016

Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia

scientific article published on 26 November 2018

Targeting cytokines in ALPS: it's FAShionable

scientific article published on 01 February 2014

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies

artículo científico publicado en 2012

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.

artículo científico publicado en 2014

The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.

artículo científico publicado en 2014

The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.

artículo científico publicado en 2016

Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia

scientific article published on 01 October 2018

Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome

scientific article published on 20 June 2019

Toxicity management for patients receiving novel T-cell engaging therapies.

artículo científico publicado en 2014

Lista de obras de David T Teachey

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

Atypical Chronic Myeloid Leukemia in Two Pediatric Patients.

Autoimmune lymphoproliferative syndrome: more than a FAScinating disease.

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition

Cellular therapy: Immune-related complications

Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia

Chimeric antigen receptor T cells for sustained remissions in leukemia

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia

Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome

Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.

Cytokine Release Syndrome after Haploidentical Stem Cell Transplantation.

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

Deep Immune Profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19

Development of hemolytic paroxysmal nocturnal hemoglobinuria without graft loss following hematopoietic stem cell transplantation for acquired aplastic anemia

Diagnosis and management of autoimmune cytopenias in childhood

Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases.

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.

Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.

Excellent outcomes for patients with B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses

Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors

Hypofibrinogenemia Is Associated With Poor Outcome and Secondary Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome in Pediatric Severe Sepsis.

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia

JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.

Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model.

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy

Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function.

Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia

Neurotoxicity after CTL019 in a pediatric and young adult cohort

New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome

Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling.

Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children

PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia

Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction

Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia.

Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice.

Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)

Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop

Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?

Severe Mucha-Habermann-Like Ulceronecrotic Skin Disease in T-Cell Acute Lymphoblastic Leukemia Responsive to Basiliximab and Stem Cell Transplant

Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

Somatic ALPS: a FAScinating condition

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date

Statins are active in acute lymphoblastic leukaemia (ALL): a therapy that may treat ALL and prevent avascular necrosis.

Successful Treatment of Recurrent Autoimmune Cytopenias in the Context of Sinus Histiocytosis With Massive Lymphadenopathy Using Sirolimus.

T-cell acute lymphoblastic leukemia.

Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia

Targeting cytokines in ALPS: it's FAShionable

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.

The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.

The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.

Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia

Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome

Toxicity management for patients receiving novel T-cell engaging therapies.